Table 1.
Characteristics of the included studies and outcome events.
| Study (Clinical trial registration) | Centers | Publication | Treatment group, (No. of participants) | Total number | Mean age (Years) | Male (%) | Study period | Mainly included Outcome Events |
|---|---|---|---|---|---|---|---|---|
| Sprigg et al. (19) (ISRCTN50867461) |
1 | Journal of Stroke and Cerebrovascular Diseases | TXA(n = 16)vs. PLA (n = 8) |
24 | TXA(67.9)vs. PLA(68.5)vs. Total(68.1) |
TXA(62.5vs. PLA(50)vs. Total(62.5) |
12 months | A, B, C, D, E, F, G |
| Arumugam et al. (18) (-) |
1 | The Malaysian journal of medical sciences | TXA(n = 15)vs. PLA(n = 15) |
30 | Total(52.9) | Total(60) | 12 months | A, B, C, D, G |
| Sprigg et al. (20) (ISRCTN93732214) |
124 | Lancet | TXA(n = 1,161)vs. PLA(n = 1,164) |
2325 | TXA(69.1)vs. PLA(68.7) | TXA(55)vs. PLA(57) |
55 months | A, B, C, D, E, F, H |
| Meretoja et al. (21) (NCT01702636) |
13 | Lancet Neurol | TXA(n = 50)vs. PLA(n = 50) |
100 | TXA(73.0)vs. PLA(71.0) | TXA(70)vs. PLA(54) |
78 months | A, B, C, D, H |
PLA, Placebo; A, No hematoma expansion (the number of hematoma expansion subtract from total); B, Change in hematoma volume from baseline; C, Death; D, Thromboembolic events; E, Neurological deterioration; F, Infection; G, Craniotomy; H, mRS.